Talecris stock slips as demand for blood-plasma products wane

12/1/2009 | News & Observer (Raleigh, N.C.), The

Shares of Talecris, a maker of blood plasma-derived treatments for various immune disorders, dropped Monday by almost 20% since reaching a high in early November, amid concerns that the company won't be able to sustain its rising profit into the coming year. Analysts say the economic downturn could create an oversupply in blood-plasma products as more people donate.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD